Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IzotropicFRA:1R3 +1.56%28 Forward PE Ratio is 1.66 as of Aug. 08, 2026. GuruFocus rates FRA:1R3 with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 87 Medical Diagnostics & Research companies, Izotropic ranks better than 94.25% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Izotropic Forward PE Ratio Related Terms
Izotropic Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Izotropic's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Izotropic Forward PE Ratio Chart
Izotropic Annual Data
Trend
Forward PE Ratio
Izotropic Quarterly Data
2026-01
Forward PE Ratio
1.96
FRA:1R3 vs TMO, DHR, IDXX: Forward PE Ratio Comparison
For the Diagnostics & Research subindustry, Izotropic's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Izotropic Forward PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Izotropic's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Izotropic's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Izotropic (FRA:1R3) has a Forward PE Ratio of 1.66 as of Aug. 08, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Izotropic and its competitors. According to the industry distribution chart, Izotropic ranks #5 out of 87 companies in the Medical Diagnostics & Research industry, placing it in the top 5.7%.
Is Izotropic's Forward PE Ratio too high?
Izotropic's current Forward PE Ratio is 1.66. The Medical Diagnostics & Research industry median Forward PE Ratio is 23.08. Izotropic's value of 1.66 is 92.8% below this industry median. Based on the distribution chart, Izotropic ranks #5 out of 87 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Izotropic has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Izotropic's Forward PE Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Izotropic ranks #5 out of 87 companies for Forward PE Ratio. This places Izotropic in the top 6% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 23.08. Izotropic's value of 1.66 is 92.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Diagnostics & Research company?
The median Forward PE Ratio among Medical Diagnostics & Research companies is 23.08, based on 87 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Izotropic's current Forward PE Ratio of 1.66 is 92.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Izotropic and its competitors. For the Medical Diagnostics & Research industry, the median Forward PE Ratio is 23.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Izotropic's current Forward PE Ratio is 1.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Izotropic stock overvalued right now?
Izotropic (FRA:1R3) has a current Forward PE Ratio of 1.66. The current Forward PE Ratio is 1.66 and 92.8% below the Medical Diagnostics & Research industry median of 23.08. Izotropic's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Izotropic (FRA:1R3), the current Forward PE Ratio is 1.66 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Izotropic Corp is a research and development company specializing in cancer research and early detection for breast cancer. It is engaged in advancing breast cancer imaging through the commercialization of medical imaging technologies. The company's current focus is on the commercialization of its first medical imaging device, IzoView, a dedicated Breast CT Imaging System, developed to provide high resolution, true 3D volumetric visualization of the breast without compression for breast cancer detection and diagnosis.
28GF Score
Get the complete analysis for FRA:1R3
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1R3 has been successfully added to your 
